Braintree HalfLytely Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company hopes to achieve 50%-60% market penetration for the half-volume colonoscopy bowel cleanser. Braintree estimates 4 mil. patients undergo colonoscopies annually.